Boston Scientific’s BSX robust expansion of operations across different geographies outside the United States is poised to help it grow in the upcoming quarters. The company’s Electrophysiology (EP) ...

Boston Scientific Corporation (NYSE ... from the OPTION global clinical trial of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Key findings from the study comparing the device ...

If you’re on the fence about investing in Becton, Dickinson and Company or Boston Scientific Corporation ... artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure ...

Boston Scientific is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53 BSX has reported YOY quarterly earnings growth of -6.3% and gross profit margins ...

Boston Scientific is diving into the field of intravascular lithotripsy, with a $664 million deal to pick up Bolt Medical and ...

Boston Scientific has agreed to acquire the rest of Bolt Medical, the developer of an intravascular-lithotripsy, or IVL, laser-based platform for the treatment of coronary and peripheral artery ...

On Oct. 10, Boston Scientific sent an urgent medical device advisory to all affected customers with recommendations. Boston's device is used in ablation procedures to treat recurrent symptomatic ...

Boston Scientific Corporation (BSX), headquartered in Marlborough, Massachusetts, develops, manufactures, and markets medical devices for use in various interventional medical specialties globally.

According to the company, about 70% of the safety mode events occurred during a patient’s clinic visit, while the device was connected to a Latitude programmer. Boston Scientific said it is ...